1
|
Evaluation of Substituted Pyrazole-Based Kinase Inhibitors in One Decade (2011-2020): Current Status and Future Prospects. Molecules 2022; 27:molecules27010330. [PMID: 35011562 PMCID: PMC8747022 DOI: 10.3390/molecules27010330] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2021] [Revised: 12/29/2021] [Accepted: 12/31/2021] [Indexed: 11/17/2022] Open
Abstract
Pyrazole has been recognized as a pharmacologically important privileged scaffold whose derivatives produce almost all types of pharmacological activities and have attracted much attention in the last decades. Of the various pyrazole derivatives reported as potential therapeutic agents, this article focuses on pyrazole-based kinase inhibitors. Pyrazole-possessing kinase inhibitors play a crucial role in various disease areas, especially in many cancer types such as lymphoma, breast cancer, melanoma, cervical cancer, and others in addition to inflammation and neurodegenerative disorders. In this article, we reviewed the structural and biological characteristics of the pyrazole derivatives recently reported as kinase inhibitors and classified them according to their target kinases in a chronological order. We reviewed the reports including pyrazole derivatives as kinase inhibitors published during the past decade (2011-2020).
Collapse
|
2
|
Gamal El-Din MM, El-Gamal MI, Abdel-Maksoud MS, Yoo KH, Oh CH. Design, synthesis, in vitro potent antiproliferative activity, and kinase inhibitory effects of new triarylpyrazole derivatives possessing different heterocycle terminal moieties. J Enzyme Inhib Med Chem 2020; 34:1534-1543. [PMID: 31452407 PMCID: PMC6720312 DOI: 10.1080/14756366.2019.1653292] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
A new series of triarylpyrazole derivatives having different heterocycle terminal groups have been designed and synthesised. Compounds 1h–j and 1l exhibited the highest mean percentage inhibition against the 58 cancer cell lines at a concentration of 10 μM, and thus were next examined in 5-dose testing mode to detect their IC50 value. The four compounds showed stronger antiproliferative activities upon comparing their results with sorafenib as a reference compound. Among them, compounds 1j and 1l possessing N-ethylpiperazinyl and N-benzylpiperazinyl terminal moiety through ethylene linker showed the greatest values of mean percentage inhibition (97.72 and 107.18%, respectively) over the 58-cell line panel at 10 μM concentration. The IC50 values of compound 1j over several cancer cell lines were in submicromolar scale (0.26 ∼ 0.38 μM). Moreover, the compounds 1j and 1l showed highly inhibitory activities (99.17 and 97.92%) against V600E-B-RAF kinase.
Collapse
Affiliation(s)
- Mahmoud M Gamal El-Din
- Pharmaceutical and Drug Industries Research Division, National Research Centre , Dokki-Giza , Egypt
| | - Mohammed I El-Gamal
- Department of Medicinal Chemistry, College of Pharmacy, University of Sharjah , Sharjah , UAE.,Sharjah Institute for Medical Research, University of Sharjah , Sharjah , UAE.,Department of Medicinal Chemistry, Faculty of Pharmacy, University of Mansoura , Mansoura , Egypt
| | - Mohammed S Abdel-Maksoud
- Pharmaceutical and Drug Industries Research Division, National Research Centre , Dokki-Giza , Egypt
| | - Kyung Ho Yoo
- Chemical Kinomics Research Center, Korea Institute of Science and Technology , Seoul , Republic of Korea
| | - Chang-Hyun Oh
- Center for Biomaterials, Korea Institute of Science and Technology , Seoul , Republic of Korea.,Department of Biomolecular Science, University of Science and Technology , Daejeon , Republic of Korea
| |
Collapse
|
3
|
Abdel-Maksoud MS, El-Gamal MI, Gamal El-Din MM, Oh CH. Design, synthesis, in vitro anticancer evaluation, kinase inhibitory effects, and pharmacokinetic profile of new 1,3,4-triarylpyrazole derivatives possessing terminal sulfonamide moiety. J Enzyme Inhib Med Chem 2018; 34:97-109. [PMID: 30362383 PMCID: PMC6211260 DOI: 10.1080/14756366.2018.1530225] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The present work describes the design and synthesis of a novel series of 1,3-diaryl-4-sulfonamidoarylpyrazole derivatives 1a–q and 2a–q and their in vitro biological activities. The target compounds were evaluated for antiproliferative activity against NCI-60 cell line panel. Compounds 1c, 1g, 1k–m, 1o, 2g, 2h, 2k–m, 2o, and 2q showed the highest mean inhibition percentages at 10 µM single-dose testing and were selected to be tested at 5-dose mode. The ICs50 of the most potent compounds were determined over the 60 cell lines. Compound 2l exhibited the strongest activity against different cell lines with IC50 0.33 µM against A498 renal cancer cell line. Compound 2l was tested over a panel of 20 kinases to determine its molecular target(s), and its IC50 values over the most sensitive kinases were defined. In vitro stability and in vivo pharmacokinetic profile of compound 2l was also investigated.
Collapse
Affiliation(s)
- Mohammed S Abdel-Maksoud
- a Medicinal & Pharmaceutical Chemistry Department , Pharmaceutical and Drug Industries Research Division, National Research Centre (NRC) , Dokki , Giza , Egypt
| | - Mohammed I El-Gamal
- b Department of Medicinal Chemistry , College of Pharmacy, University of Sharjah , Sharjah , United Arab Emirates.,c Sharjah Institute for Medical Research, University of Sharjah , Sharjah , United Arab Emirates.,d Department of Medicinal Chemistry , Faculty of Pharmacy, University of Mansoura , Mansoura , Egypt
| | - Mahmoud M Gamal El-Din
- a Medicinal & Pharmaceutical Chemistry Department , Pharmaceutical and Drug Industries Research Division, National Research Centre (NRC) , Dokki , Giza , Egypt
| | - Chang Hyun Oh
- e Center for Biomaterials, Korea Institute of Science and Technology (KIST) , Cheongryang , Seoul , Republic of Korea.,f Department of Biomolecular Science , University of Science and Technology (UST) , Daejeon , Yuseong-gu Republic of Korea
| |
Collapse
|
4
|
Abdel-Maksoud MS, El-Gamal MI, Gamal El-Din MM, Choi Y, Choi J, Shin JS, Kang SY, Yoo KH, Lee KT, Baek D, Oh CH. Synthesis of New Triarylpyrazole Derivatives Possessing Terminal Sulfonamide Moiety and Their Inhibitory Effects on PGE₂ and Nitric Oxide Productions in Lipopolysaccharide-Induced RAW 264.7 Macrophages. Molecules 2018; 23:molecules23102556. [PMID: 30301280 PMCID: PMC6222820 DOI: 10.3390/molecules23102556] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2018] [Revised: 09/29/2018] [Accepted: 10/02/2018] [Indexed: 01/20/2023] Open
Abstract
This article describes the design, synthesis, and in vitro anti-inflammatory screening of new triarylpyrazole derivatives. A total of 34 new compounds were synthesized containing a terminal arylsulfonamide moiety and a different linker between the sulfonamide and pyridine ring at position 4 of the pyrazole ring. All the target compounds were tested for both cytotoxicity and nitric oxide (NO) production inhibition in lipopolysaccharide (LPS)-induced RAW 264.7 macrophages. Compounds 1b, 1d, 1g, 2a, and 2c showed the highest NO inhibition percentages and the lowest cytotoxic effect. The most potent derivatives were tested for their ability to inhibit prostaglandin E₂ (PGE₂) in LPS-induced RAW 264.7 macrophages. The IC50 for nitric oxide inhibition, PGE₂ inhibition, and cell viability were determined. In addition, 1b, 1d, 1g, 2a, and 2c were tested for their inhibitory effect on LPS-induced inducible nitric oxide synthase (iNOS) and Cyclooxygenase 2 (COX-2) protein expression as well as iNOS enzymatic activity.
Collapse
Affiliation(s)
- Mohammed S Abdel-Maksoud
- Medicinal & Pharmaceutical Chemistry Department, Pharmaceutical and Drug Industries Research Division, National Research Centre (NRC), Dokki, Giza 12622, Egypt.
| | - Mohammed I El-Gamal
- Department of Medicinal Chemistry, College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates.
- Sharjah Institute for Medical Research, University of Sharjah, Sharjah 27272, United Arab Emirates.
- Department of Medicinal Chemistry, Faculty of Pharmacy, University of Mansoura, Mansoura 35516, Egypt.
| | - Mahmoud M Gamal El-Din
- Medicinal & Pharmaceutical Chemistry Department, Pharmaceutical and Drug Industries Research Division, National Research Centre (NRC), Dokki, Giza 12622, Egypt.
| | - Yunji Choi
- Department of Chemistry, Hanseo University, Seosan 31962, Korea.
| | - Jungseung Choi
- Department of Chemistry, Hanseo University, Seosan 31962, Korea.
| | - Ji-Sun Shin
- Department of Pharmaceutical Biochemistry, College of Pharmacy, Kyung Hee University, Seoul 02792 Korea.
- Department of Life and Nanopharmaceutical Science, College of Pharmacy, Kyung Hee University, Seoul 130-650, Korea.
| | - Shin-Young Kang
- Department of Pharmaceutical Biochemistry, College of Pharmacy, Kyung Hee University, Seoul 02792 Korea.
- Department of Life and Nanopharmaceutical Science, College of Pharmacy, Kyung Hee University, Seoul 130-650, Korea.
| | - Kyung Ho Yoo
- Department of Chemistry, Hanseo University, Seosan 31962, Korea.
| | - Kyung-Tae Lee
- Department of Pharmaceutical Biochemistry, College of Pharmacy, Kyung Hee University, Seoul 02792 Korea.
- Department of Life and Nanopharmaceutical Science, College of Pharmacy, Kyung Hee University, Seoul 130-650, Korea.
| | - Daejin Baek
- Department of Chemistry, Hanseo University, Seosan 31962, Korea.
| | - Chang-Hyun Oh
- Center for Biomaterials, Korea Institute of Science and Technology, Cheongryang, Seoul 130-650, Korea.
- Department of Biomolecular Science, University of Science and Technology, Daejeon, Yuseong-gu 34113, Korea.
| |
Collapse
|
5
|
El-Gamal MI, Park BJ, Oh CH. Synthesis, in vitro antiproliferative activity, and kinase inhibitory effects of pyrazole-containing diarylureas and diarylamides. Eur J Med Chem 2018; 156:230-239. [DOI: 10.1016/j.ejmech.2018.07.008] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2018] [Revised: 06/23/2018] [Accepted: 07/04/2018] [Indexed: 01/07/2023]
|
6
|
Design and synthesis of a new series of highly potent RAF kinase-inhibiting triarylpyrazole derivatives possessing antiproliferative activity against melanoma cells. Future Med Chem 2016; 8:2197-2211. [PMID: 27845592 DOI: 10.4155/fmc-2016-0057] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
BACKGROUND Inhibition of V600E-B-RAF kinase represents a potential avenue for melanoma treatment. Herein, a series of 1,3,4-triarylpyrazoles possessing amide linker were designed, synthesized and evaluated for RAF kinase inhibition. RESULTS Compounds 1d and 1f were more potent than sorafenib against A375 cell line, and their selectivity indexes toward A375 than HS27 fibroblasts were 25.43 and 45.83, respectively. Compound 1f was more potent against the melanoma cell lines with B-RAF V600E mutation than melanoma cells with NRAS mutation and normal skin epithelial cells. Compounds 1d and 1f showed strong potency and selectivity against V600E-B-RAF kinase with IC50 values of 3.80 and 2.98 nM, respectively. Molecular docking studies revealed their binding mode. CONCLUSION Potent and selective V600E-B-RAF antimelanoma agents were discovered. [Formula: see text].
Collapse
|
7
|
Design, synthesis, broad-spectrum antiproliferative activity, and kinase inhibitory effect of triarylpyrazole derivatives possessing arylamides or arylureas moieties. Eur J Med Chem 2016; 119:122-31. [DOI: 10.1016/j.ejmech.2016.04.048] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2015] [Revised: 04/17/2016] [Accepted: 04/18/2016] [Indexed: 01/07/2023]
|
8
|
Gamal El-Din MM, El-Gamal MI, Abdel-Maksoud MS, Yoo KH, Baek D, Choi J, Lee H, Oh CH. Design, synthesis, and in vitro antiproliferative and kinase inhibitory effects of pyrimidinylpyrazole derivatives terminating with arylsulfonamido or cyclic sulfamide substituents. J Enzyme Inhib Med Chem 2016; 31:111-122. [PMID: 27255180 DOI: 10.1080/14756366.2016.1190715] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
A novel series of substituted pyrimidine compounds bearing N-phenylpyrazole and terminating with aryl and cyclic sulfonamido moiety were designed, synthesized, and evaluated in vitro as antiproliferative agents against a panel of 53 cell lines of different tissues at the NCI. Among them, compound 1d with p-chlorobenzenesulfonamido terminal moiety, ethylene spacer, and 4-chloro-3-methoxyphenyl ring at position 3 of the pyrazole nucleus showed the highest mean percentage inhibition value over the whole cancer cell line panel at 10 μM concentration. It showed broad-spectrum antiproliferative activity over many cell lines of different cancer types. For instance, compound 1d inhibited the growth of HL-60 (TB), SR leukemia, and T-47D and MCF-7 breast cancer cell line by 135.92%, 119.44%, 95.32%, and 82.03% at 10 μM, respectively. And it inhibited the growth of COLO 205 colon, HT29 colon, BT-549 breast, and ACHN renal cancer cell lines by more than 80% at the same test concentration. However, testing compound 1d upon determining its IC50 against the most sensitive cell lines showed to good extent selectivity against HT29 colon cancer cell line than HL-60 leukemia and MRC-5 lung fibroblasts (normal cells). Compound 1d was further tested against 12 kinases of different kinase families, and the highest inhibitory effect was exerted against RAF1, V600E-B-RAF, and V600K-B-RAF kinases.
Collapse
Affiliation(s)
- Mahmoud M Gamal El-Din
- a Center for Biomaterials, Korea Institute of Science and Technology , Seoul , Republic of Korea.,b Department of Biomolecular Science , University of Science and Technology , Daejeon , Republic of Korea.,c Pharmaceutical and Drug Industries Research Division, National Research Centre , Dokki-Giza , Egypt
| | - Mohammed I El-Gamal
- d Department of Medicinal Chemistry , College of Pharmacy, University of Sharjah , Sharjah , United Arab Emirates.,e Sharjah Institute for Medical Research, University of Sharjah , Sharjah , United Arab Emirates.,f Department of Medicinal Chemistry , Faculty of Pharmacy, University of Mansoura , Mansoura , Egypt
| | - Mohammed S Abdel-Maksoud
- a Center for Biomaterials, Korea Institute of Science and Technology , Seoul , Republic of Korea.,b Department of Biomolecular Science , University of Science and Technology , Daejeon , Republic of Korea.,c Pharmaceutical and Drug Industries Research Division, National Research Centre , Dokki-Giza , Egypt
| | - Kyung Ho Yoo
- g Chemical Kinomics Research Center, Korea Institute of Science and Technology , Seoul , Republic of Korea , and
| | - Daejin Baek
- h Department of Chemistry , Hanseo University , Seosan , Republic of Korea
| | - Jungseung Choi
- h Department of Chemistry , Hanseo University , Seosan , Republic of Korea
| | - Huiseong Lee
- h Department of Chemistry , Hanseo University , Seosan , Republic of Korea
| | - Chang-Hyun Oh
- a Center for Biomaterials, Korea Institute of Science and Technology , Seoul , Republic of Korea.,b Department of Biomolecular Science , University of Science and Technology , Daejeon , Republic of Korea
| |
Collapse
|
9
|
El-Gamal MI, Choi HS, Yoo KH, Baek D, Oh CH. Antiproliferative diarylpyrazole derivatives as dual inhibitors of the ERK pathway and COX-2. Chem Biol Drug Des 2013; 82:336-47. [PMID: 23834707 DOI: 10.1111/cbdd.12186] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2012] [Revised: 05/02/2013] [Accepted: 07/01/2013] [Indexed: 12/19/2022]
Abstract
A series of 3,4-diarylpyrazole-1-carboxamide derivatives was designed and synthesized. A selected group of the target compounds was tested for in vitro antiproliferative activities over a panel of 60 cancer cell lines at the National Cancer Institute (NCI, Bethesda, MD, USA) at a single-dose concentration of 10 μm, and the four most active compounds 9a, 9l, 9n, and 10o were further tested in a five-dose testing mode to determine their IC50 values over the 60 cell lines. In addition, a selected group of target compounds were tested for inhibitory effect over cyclooxygenase isozymes. Compounds 9a, 9l, 9n, and 10o were also tested for MEK and ERK kinase inhibitory activity using Western blot assay. Compound 10o was selective toward melanoma cell line subpanel, and its antiproliferative activity may be attributed to selective cyclooxygenase-2 inhibition and ERK pathway inhibition.
Collapse
Affiliation(s)
- Mohammed I El-Gamal
- Center for Biomaterials, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul, 130-650, Korea; Department of Biomolecular Science, University of Science and Technology, 113 Gwahangno, Yuseong-gu, Daejeon, 305-333, Korea; Department of Medicinal Chemistry, Faculty of Pharmacy, University of Mansoura, Mansoura, 35516, Egypt
| | | | | | | | | |
Collapse
|
10
|
El-Gamal MI, Park YS, Chi DY, Yoo KH, Oh CH. New triarylpyrazoles as broad-spectrum anticancer agents: design, synthesis, and biological evaluation. Eur J Med Chem 2013; 65:315-22. [PMID: 23732996 DOI: 10.1016/j.ejmech.2013.04.067] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2013] [Revised: 04/29/2013] [Accepted: 04/30/2013] [Indexed: 01/07/2023]
Abstract
A new series of diarylureas and diarylamides possessing 1,3,4-triarylpyrazole scaffold was designed and synthesized. Their in vitro antiproliferative activities against NCI-60 cell line panel were tested. Most of the compounds showed strong and broad-spectrum antiproliferative activities. Compound 18 exerted sub-micromolar IC50 values over all the subpanels of nine different cancer types. Its IC50 value over MDA-MB-435 melanoma cell line was 27 nM. Compounds 10-13, 22, and 23 possessing urea spacer exerted lethal effect over the NCI-60 panel with mean %inhibitions more than 100% in single-dose testing. Compounds 13 and 23 with urea linker and 3',5'-bis(trifluoromethyl)phenyl terminal ring showed the highest mean %inhibition over the NCI-60 panel in single-dose testing, and showed high potencies and broad-spectrum anticancer activities in five-dose testing.
Collapse
Affiliation(s)
- Mohammed I El-Gamal
- Center for Biomaterials, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul 130-650, Republic of Korea.
| | | | | | | | | |
Collapse
|